莎普爱思(603168) - 2019 Q1 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 146,866,878.29, representing a decline of 21.10% year-on-year[5] - Net profit attributable to shareholders was CNY 19,439,386.53, down 52.42% compared to the same period last year[5] - Basic earnings per share decreased by 53.85% to CNY 0.06[5] - Cash flow from operating activities was CNY 46,256,242.12, a significant drop of 48.57% year-on-year[5] - The net profit attributable to shareholders for the current period was CNY 19,439,386.53, representing a decline of 52.42% year-on-year, primarily due to decreased sales of eye drops and cefixime products[13] - Cash received from sales of goods and services was CNY 165,400,973.90, down 39.61% compared to the same period last year, mainly due to a decline in sales of eye drop products[13] - Total operating revenue for Q1 2019 was ¥146,866,878.29, a decrease of 21.06% compared to ¥186,147,655.81 in Q1 2018[31] - Net profit for Q1 2019 was ¥19,439,386.53, representing a decline of 52.41% from ¥40,852,483.69 in Q1 2018[31] - Earnings per share for Q1 2019 were ¥0.06, compared to ¥0.13 in Q1 2018, reflecting a 53.85% decrease[32] - The total profit for Q1 2019 was ¥22,895,131.04, a decrease of 53.83% from ¥49,532,477.88 in Q1 2018[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,642,608,778.89, a decrease of 0.36% compared to the end of the previous year[5] - The company's current assets increased to CNY 916,797,157.38 from CNY 911,470,332.13, primarily driven by an increase in cash and cash equivalents, which rose to CNY 203,469,203.15 from CNY 145,164,499.82[22] - Accounts receivable decreased to CNY 153,405,455.57 from CNY 187,083,814.58, with notes receivable dropping to CNY 120,761,621.17 from CNY 160,228,317.39[22] - Inventory levels decreased to CNY 81,920,992.20 from CNY 91,165,519.56, indicating a reduction in stock[22] - Total liabilities decreased to CNY 141,990,305.51 from CNY 167,414,941.23, reflecting a reduction in current liabilities[25] - The company's equity increased to CNY 1,500,618,473.38 from CNY 1,481,179,086.85, showing a growth in retained earnings[25] - The company's total liabilities as of Q1 2019 were ¥117,786,380.66, a decrease from ¥134,995,258.04 in the previous year[31] Cash Flow - In Q1 2019, Zhejiang Shapuaisi Pharmaceutical Co., Ltd. reported a net cash flow from operating activities of CNY 46,256,242.12, a decrease of 48.4% compared to CNY 89,934,958.46 in Q1 2018[37] - The total cash inflow from operating activities was CNY 173,797,545.92, down 37.7% from CNY 278,796,785.85 in the same period last year[37] - The company recorded a net cash flow from investing activities of CNY 12,048,461.21, a significant improvement from a negative cash flow of CNY -289,869,924.26 in Q1 2018[38] - Cash and cash equivalents at the end of Q1 2019 amounted to CNY 203,469,203.15, compared to CNY 238,479,657.47 at the end of Q1 2018, reflecting a decrease of 14.7%[39] - The cash outflow from operating activities totaled CNY 127,541,303.80, down 32.4% from CNY 188,861,827.39 in Q1 2018[38] Shareholder Information - The total number of shareholders at the end of the reporting period was 25,173[10] - The largest shareholder, Chen Dekang, holds 28.97% of the shares, totaling 93,462,228 shares[10] Government Support and Other Income - The company received government subsidies amounting to CNY 108,500 during the reporting period[8] - The company reported a total of CNY -1,198,020.24 in non-operating income and expenses[8] - The company received project subsidies amounting to CNY 8,396,572.02, an increase of 70.63% year-on-year, attributed to increased project support received[13] - Other income for Q1 2019 was ¥108,500.00, down from ¥600,000.00 in Q1 2018[31] Research and Development - The company is conducting consistency evaluation for benzalkonium chloride eye drops, with significant progress reported in research and development[15] - Research and development expenses for Q1 2019 were ¥4,314,377.24, slightly down from ¥4,600,158.37 in Q1 2018[31] Investment Activities - The company has utilized CNY 4.32 billion for entrusted wealth management, with all products redeemed on time as of March 31, 2019[14] - The company plans to continue investing in low-risk short-term financial products, with a maximum of CNY 500 million allocated for such investments[14] - The cash inflow from investment activities was CNY 36,323,271.23, a decrease of 72.5% from CNY 131,523,315.07 in the same quarter last year[38] Future Outlook - The company has not indicated any significant changes in its profit forecast or major operational commitments for the upcoming reporting period[20] - The company plans to continue focusing on improving operational efficiency and exploring new market opportunities in the pharmaceutical sector[39]